FUREN Group Pharmaceutical Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares FUREN Group Pharmaceutical Co Ltd with three other
companies in this sector in China:
Zhejiang Conba Pharmaceutical Co., Ltd.
sales of 6.78 billion Chinese Renmimbi [US$986.74 million]
of which 98%
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
(6.36 billion Chinese Renmimbi [US$924.73 million]
of which 66%
was Chinese Medicine), and
Guizhou Xinbang Pharmaceutical Company Limited
(6.58 billion Chinese Renmimbi [US$956.97 million]
of which 64%
was Pharmaceutical industry).
FUREN Group Pharmaceutical Co Ltd reported sales of 6.32 billion Chinese Renmimbi (US$918.73 million)
December of 2018.
increase of 8.9%
versus 2017, when the company's sales were 5.80 billion Chinese Renmimbi.
Sales at FUREN Group Pharmaceutical Co Ltd have increased during each of the previous five years
(and since 2013, sales have increased a total of 1,518%).
Sales of Other Operations saw an increase
that was more than double the company's growth rate: sales were up
1,380.2% in 2018, from
7.12 million Chinese Renmimbi to 105.42 million Chinese Renmimbi.
FUREN Group Pharmaceutical Co Ltd also saw significant increases in sales in
Pharmaceutical Business (up 37.1% to 1.16 billion Chinese Renmimbi)